P-1019. Comparative Analysis of C. difficile Isolates from Recurrent and Non-Recurrent Infections: Outcomes, Antimicrobial Susceptibility, and Biofilm Formation

TL;DR

This study compared C. difficile isolates from patients with recurrent and non-recurrent infections but found no significant differences in antibiotic susceptibility or biofilm formation.

Contribution

The study provides a comparative analysis of C. difficile isolates from recurrent and non-recurrent infections focusing on antimicrobial susceptibility and biofilm formation.

Findings

All isolates were 100% susceptible to metronidazole, vancomycin, omadacycline, eravacycline, and tigecycline.

No significant differences in biofilm formation were observed between isolates from recurrent and non-recurrent CDI.

Antibiotic exposure was common in both recurrent and non-recurrent CDI patients prior to hospitalization.

Abstract

Clostridioides difficile infection (CDI) is a serious diarrheal illness caused by microbiota disruption, mainly after antibiotic use. Around 20-25% of patients experience recurrence, and the risk increases for each episode. The causes of recurrence are not entirely elucidated. This study aimed to investigate differences in antibiotic susceptibility and biofilm formation between strains isolated from patients with recurrent and non-recurrent CDI.

We collected fecal samples from adult patients > 18 years old and with diarrhea, with a positive GeneXpert-positive test for

tcdB Patient demographic and clinical data were collected from electronic medical records. Clostridioides difficile was isolated using alcohol shock treatment and cultured on selective TCCFA media under anaerobic conditions. Antimicrobial susceptibility assays (for Metronidazole, Tigecycline, Vancomycin, Omadacycline, Eravacycline) were assessed using e-test strips (Liofichem), with interpretation following CLSI guidelines. Biofilm biomass was quantified using the crystal violet staining technique.

54 C. difficile isolates were analyzed: 23 from R-CDI patients and 31 from NR-CDI patients. Antibiotic exposure within 14 days before hospitalization occurred in most patients with NR-CDI (91.30%) and R-CDI (79.47%). The predominant toxinotype was

tcdA⁺tcdB⁺cdt- for both R-CDI and NR-CDI patients. All isolates were 100% susceptible to metronidazole, vancomycin, omadacycline, eravacycline and tigecycline. Among R-CDI, MIC ranges were 0.25-4 mg/mL for metronidazole and 0.38-8 mg/mL for vancomycin. For NR-CDI, MIC ranges were 0.75-4 mg/mL for metronidazole and 0.5-4mg/mL for vancomycin. Biofilm formation was observed in most isolates, and they were categorized as low, moderate, or high producers, with maximum biofilm formation after 48h. The biofilm biomass was strain and time-dependent, but no significant differences between R-CDI and NR-CDI strains was observed at any of the time points analyzed.

Our findings in this small study did not find significant differences in antimicrobial susceptibility, biofilm formation and microbiological characteristics among clinical isolates from recurrent and non-recurrent CDI.

All Authors: No reported disclosures